COMMUNIQUÉS West-GlobeNewswire

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08/05/2018 - 22:03

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM ), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies [...]

Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

08/05/2018 - 22:02

Xenon’s novel clinical stage epilepsy candidates, XEN1101 and XEN901, to be presented at upcoming 14th Eilat Conference on New Antiepileptic Drugs and Devices on May 15, 2018 BURNABY, British Columbia, May 08, 2018 ( [...]

INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

08/05/2018 - 22:02

PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today [...]

Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results

08/05/2018 - 22:01

HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

08/05/2018 - 22:01

LIVONIA, Mich., May 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP ), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, [...]

MyoKardia Reports First Quarter 2018 Financial Results

08/05/2018 - 22:01

Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK ), a clinical-stage biopharmaceutical company [...]

Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights

08/05/2018 - 22:01

Company booked net ZILRETTA ® sales of $2.2 million in Q1 Positive developments in Medicare reimbursement with CMS issuing Q code for ZILRETTA (effective 7/1/18) and recommending dedicated J code (effective 1/1/19) [...]

T2 Biosystems Reports First Quarter 2018 Financial Results and Provides Corporate Update

08/05/2018 - 22:01

Quarterly Product Revenue Up 66% Year-Over-Year On Track for Potential FDA Clearance of T2Bacteria Panel in the Second Quarter 2018 LEXINGTON, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ) [...]

Tempus Announces New Initiative to Support Physicians Efforts to Deliver Personalized Medicine

08/05/2018 - 19:27

CHICAGO, May 08, 2018 (GLOBE NEWSWIRE) -- Tempus today announced a new initiative that will allow physicians to sequence a second patient sample without additional charge, removing a barrier that oftentimes stands in [...]

GW Pharmaceuticals to Present at Bank of America Merrill Lynch 2018 Health Care Conference

08/05/2018 - 19:00

LONDON and CARLSBAD, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH ) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing [...]

Brain Tumor Advocates from Across the United States “Head to the Hill” to Meet with Members of Congress

08/05/2018 - 19:00

National Brain Tumor Society’s Annual Head to the Hill Advocacy Day puts brain tumor research funding, treatment development, and patient care on the legislative agenda in Washington, D.C. Washington, D.C., May 08, 2018 [...]

Emblem enters into Advisory Agreement with e.vestor Communications Inc.

08/05/2018 - 14:00

TORONTO, May 08, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSX-V: EMC ) (TSX-V:EMC.WT) (" Emblem " or the " Corporation ") is pleased to announce the appointment of e.vestor Communications Inc. (“ EVC ”) as the Corporation [...]

Altimmune to Announce First Quarter 2018 Financial Results on May 16

08/05/2018 - 14:00

GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March [...]

CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis

08/05/2018 - 14:00

NEWARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]

CrownBio Demonstrates Advantages of Innovative Translational Oncology Platform in Scientific Posters at AACR 2018 Meeting

08/05/2018 - 14:00

SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing [...]

Teligent, Inc. Announces First Quarter 2018 Results

08/05/2018 - 14:00

BUENA, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT ), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2018 [...]

Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

08/05/2018 - 14:00

CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill [...]

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results

08/05/2018 - 14:00

-On track to begin CTX001 clinical study in hemoglobinopathies in 2018- -On track to file IND in 2018 for CTX101, allogeneic CRISPR-based CAR-T targeted toward CD19+ malignancies- -$341.8 million in cash as of March 31 [...]

Vystar Pays Off $1.1 Million of Long-Term Convertible Debt at 30% savings

08/05/2018 - 14:00

All $1.1 million of long-term convertible debt paid off for $795,000 85% of debt converted is held by current insiders & large stakeholders Vystar CEO progresses on plan to eliminate all debt WORCESTER, Mass., May [...]